Skip to main content
. 2016 Feb 10;196(6):2885–2892. doi: 10.4049/jimmunol.1402695

Table I. Patient characteristics in the second data set.

Patient No. Age (y)/Sex Type Stage TNM Classification Previous Treatment
1 82/M SSM IA pT1aN0M0
2 62/F SSM IB T1bN0M0
3 52/M SSM IB T2aN0M0
4 59/F SSM IB pT2aN0M0
5 63/F ALM IIA pT2bN0M0
6 60/M ALM IIC pT4bN0M0 OP, Rec
7 78/F SSM IIC T4bN0M0
8 64/M SSM IIIA pT4N2aM0
9 53/F SSM IIIA pT2aN1aM0
10 54/F SSM IIIB pT1bN1aM0 OP, Rec
11 63/M NM IIIB pT4bN1aM0
12 71/F SSM IIIB T1aN1bM0
13 33/F ALM IIIB pT3bN2aM0
14 78/M ALM IIIC pT4bN3M0
15 71/M ALM IV T4bN3M1c OP, CT
16 62/M MU IV pTxN0M1c OP, CT
17 56/F MU IV pTxN0M1c OP, CT
18 39/F SSM IV pTxNxM1c OP, CT, RT
19 59/F ALM IV TxN3M1c OP

ALM, acral lentiginous melanoma; CT, chemotherapy; MU, mucosal melanoma; NM, nodular melanoma; OP, operation; Rec, recurrence; RT, radiotherapy; SSM, superficial spreading melanoma TNM, Tumor-Node-Metastasis.